Get the Stockscreener App
201.24
0.45%
0.735
Overview
News
Price History
Option Chain
Financials
Why ABBV Down?
Discussions
Forecast
Dividend History
Abbvie Inc stock is traded at $201.24, with a volume of 3.45M.
It is up +0.45% in the last 24 hours and down -1.72% over the past month.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
See More
Previous Close:
$200.50
Open:
$201.05
24h Volume:
3.45M
Relative Volume:
0.49
Market Cap:
$356.05B
Revenue:
$61.16B
Net Income/Loss:
$4.19B
P/E Ratio:
85.22
EPS:
2.3614
Net Cash Flow:
$17.82B
1W Performance:
-3.63%
1M Performance:
-1.72%
6M Performance:
-11.76%
1Y Performance:
+13.76%
1-Day Range:
$200.41
$202.76
1-Week Range:
$199.81
$212.35
52-Week Range:
$176.11
$244.81
Abbvie Inc Stock (ABBV) Company Profile
Name
Abbvie Inc
Sector
Industry
Phone
(847) 932-7900
Address
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV vs LLY, JNJ, AZN, MRK
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
201.30 | 362.81B | 61.16B | 4.19B | 17.82B | 2.3614 |
LLY
Lilly Eli Co
|
916.73 | 806.72B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
231.25 | 544.73B | 96.36B | 21.04B | 19.70B | 8.6488 |
AZN
Astrazeneca Plc
|
193.66 | 303.62B | 58.80B | 10.24B | 8.98B | 3.2788 |
MRK
Merck Co Inc
|
114.77 | 278.01B | 64.93B | 18.26B | 12.36B | 7.2751 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-26 | Initiated | Canaccord Genuity | Buy |
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-08-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-10-25 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-04-25 | Downgrade | DZ Bank | Buy → Hold |
| Oct-14-25 | Downgrade | Erste Group | Buy → Hold |
| Oct-01-25 | Downgrade | HSBC Securities | Buy → Hold |
| Sep-17-25 | Upgrade | Berenberg | Hold → Buy |
| Aug-12-25 | Resumed | Piper Sandler | Overweight |
| Aug-07-25 | Upgrade | Daiwa Securities | Neutral → Outperform |
| May-14-25 | Downgrade | Citigroup | Buy → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-05-24 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Nov-22-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-04-24 | Upgrade | Argus | Hold → Buy |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jun-05-24 | Upgrade | HSBC Securities | Hold → Buy |
| May-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-29-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-18-23 | Downgrade | HSBC Securities | Buy → Hold |
| Dec-11-23 | Upgrade | Goldman | Neutral → Buy |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-30-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Resumed | UBS | Neutral |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| Jul-25-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-05-23 | Downgrade | Argus | Buy → Hold |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Feb-22-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-10-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Nov-08-22 | Downgrade | Societe Generale | Buy → Hold |
| Aug-01-22 | Downgrade | Atlantic Equities | Overweight → Neutral |
| May-23-22 | Initiated | SVB Leerink | Underperform |
| May-06-22 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Feb-28-22 | Downgrade | UBS | Buy → Neutral |
| Feb-03-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-03-22 | Reiterated | Barclays | Equal Weight |
| Feb-03-22 | Reiterated | BofA Securities | Neutral |
| Feb-03-22 | Reiterated | Goldman | Neutral |
| Jan-13-22 | Initiated | Redburn | Buy |
| Jan-12-22 | Reiterated | BMO Capital Markets | Outperform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Nov-23-21 | Upgrade | Societe Generale | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-23-20 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Jun-09-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jun-02-20 | Upgrade | Argus | Hold → Buy |
| May-18-20 | Resumed | BofA/Merrill | Neutral |
| May-12-20 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-20 | Resumed | Morgan Stanley | Overweight |
| Apr-20-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-26-19 | Reiterated | Cowen | Outperform |
| Sep-26-19 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-27-19 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jun-26-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-28-19 | Initiated | Goldman | Neutral |
| Apr-29-19 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
View All
Abbvie Inc Stock (ABBV) Latest News
AbbVie Announces $1.4B Investment in North Carolina - Contract Pharma
AbbVie to invest $1.4bn in North Carolina manufacturing campus - The Manufacturer
AbbVie price target lowered to $294 from $299 at Piper Sandler - TipRanks
AbbVie opts for North Carolina to house $1.4bn manufacturing site - Pharmaceutical Technology
ABBV (AbbVie Inc.) posts narrow Q4 2025 EPS beat, shares dip slightly in daily trading.Earnings Volatility - Cổng thông tin điện tử Tỉnh Sơn La
AbbVie to invest $1.4 billion in NC facility - The Pharma Letter
$1.4Bn AbbVie Manufacturing Campus Announced for Durham, North Carolina - Construction Review
AbbVie (ABBV): The Best Stock to Buy on a Pullback - Yahoo Finance
Spotting Winners: AbbVie (NYSE:ABBV) And Therapeutics Stocks In Q4 - The Globe and Mail
AbbVie becomes 8th of top 10 pharmaceutical manufacturers in North Carolina - The Center Square
Does AbbVie’s Durham AI Plant and Ovarian Cancer Data Reframe the Bull Case for ABBV? - Yahoo Finance
AbbVie Inc. (ABBV) Inks Licensing Agreement for Pain Medicines Development - Insider Monkey
AbbVie Invests $1.4 Billion in New Manufacturing Facility - GuruFocus
ABBV (AbbVie Inc.) edges past Q4 2025 EPS estimates, posts 8.6 percent revenue growth, shares dip 0.88 percent. - Cổng thông tin điện tử tỉnh Lào Cai
AbbVie | Pharmaceutical company to build new campus in North Carolina, bring hundreds of jobs to Durham - ABC11 Raleigh-Durham
AbbVie To Build Durham Campus, 730 Jobs - Hoodline
AbbVie (ABBV) Stock Jumps On $1.4 Billion North Carolina Campus Announcement - MEXC
Biopharma company AbbVie to create 730 jobs in Durham - WRAL
Gov. Stein announces AbbVie to build $1.4 billion manufacturing campus in durham - WUNC News
Pharma giant AbbVie plans $1.4 billion campus near Research Triangle Park - Axios
AbbVie creating 734 jobs with new $1.4 billion Durham County biopharma campus - CBS17.com
AbbVie announces $1.4 billion investment for 185-acre manufacturing campus in North Carolina - marketscreener.com
Abbvie Announces $1.4 Billion Investment For 185-Acre Manufacturing Campus In North Carolina - TradingView
AbbVie (ABBV) Unveils $1.4B Manufacturing Campus in North Caroli - GuruFocus
AbbVie to add over 700 jobs at new North Carolina campus - FirstWord Pharma
AbbVie to build $1.4B North Carolina plant By Investing.com - Investing.com Canada
AbbVie to build $1.4B North Carolina plant - Investing.com
AbbVie to build $1.4 billion manufacturing campus in North Carolina - marketscreener.com
AbbVie Selects North Carolina for New $1.4 Billion Manufacturing Campus - Investing News Network
Biopharma company Abbvie to create 730 jobs in Durham - WRAL
AbbVie announces new $1.4B manufacturing campus (ABBV:NYSE) - Seeking Alpha
AbbVie stock moves down with RSI signaling oversold conditions near $204: weekly analysis - Traders Union
AbbVie (ABBV) Earnings Expected to Grow: Should You Buy? - Yahoo Finance UK
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
How a single word could determine the future of 340B - Modern Healthcare
Operating cash flow of AbbVie from 2015 to 2025 - Statista
Assessing AbbVie (ABBV) Valuation After Recent Share Price Softness And Lofty P/E Premium - simplywall.st
UChicago Medicine marks one-year countdown to opening of AbbVie Foundation Cancer Pavilion | Newswise - Newswise
ABBV Initiated Coverage by Canaccord Genuity -- Price Target Ann - GuruFocus
Five High-Dividend Stocks With Yields Above 3%: AbbVie, Shell, and Chevron Top the List - CoinCentral
AbbVie initiated with a Buy at Canaccord - TipRanks
Bispecific Antibody Market Landscape Report 2026: A Potential $60 Opportunity by 2031Insight on More than 550 Clinical Trials - GlobeNewswire Inc.
Biologics Market: Share and Outlook Driven by Roche, Amgen, and AbbVie Leading Advanced Therapeutics - openPR.com
Here's Why AbbVie (ABBV) Fell More Than Broader Market - Yahoo Finance
AbbVie and BioLabs Team Up to Support Life Sciences Innovation in Canada - Investing News Network
AbbVie Sponsors New BioLabs Facility in Toronto - marketscreener.com
Will AbbVie's Oncology Franchise Weigh on Q1 Top-line Growth? - qz.com
AbbVie And BioLabs Team Up To Support Life Sciences Innovation In Canada - TradingView
Why I Can’t Stop Buying AbbVie Stock - Yahoo Finance
Nxera Pharma Co., Ltd. Reaches Third R&D Milestone Under Collaboration with Abbvie - marketscreener.com
Nxera to receive $10 million milestone from AbbVie deal - The Pharma Letter
Abbvie Inc Stock (ABBV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.78%
1.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):